Brief: Cocrystal Pharma -Receipt Of Authorization To Initiate Phase 2A Human Challenge Trial In U.K. For CC-42344 Product Candidate
31/10/2023 12:09
Oct 31 (Reuters) - Cocrystal Pharma Inc COCP.O :
* COCRYSTAL PHARMA -RECEIPT OF AUTHORIZATION TO INITIATE
PHASE 2A
HUMAN CHALLENGE TRIAL IN U.K. FOR CC-42344 PRODUCT CANDIDATE
* COCRYSTAL PHARMA INC-EXPECTS TO BEGIN TREATING
INFLUENZA-INFECTED SUBJECTS IN THIS TRIAL DURING Q4 OF 2023
Source text for Eikon: ID:
Further company coverage: COCP.O
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway